BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 1, 2023
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» KAT6A inhibitor with strong antileukemia activity reported
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
KAT6A inhibitor with strong antileukemia activity reported
Nov. 3, 2023
No Comments
KAT6A is a histone acetyltransferase involved in transcriptional co-activation, proliferation and differentiation of hematopoietic progenitor and stem cells. Mutations and translocations in KAT6A are oncogenic drivers in hematological malignancies.
BioWorld Science
Cancer